Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 182

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 8
Chunk 182
---
 shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 12,501,715, and we had 3,697,640 shares available for future issuance under the 2023 Plan.

14

Stock optionsThe following table presents stock option activity for the nine months ended September 30, 2025:Number ofStock OptionsWeighted-AverageExercise PriceOutstanding at December 31, 20245,834,256 $43.48 Granted948,551 33.59 Exercised(93,389)28.42 Cancelled/Forfeited(170,435)49.37 Expired(247,036)106.25 Outstanding at September 30, 20256,271,947 $39.58 Exercisable at September 30, 20254,232,483 $43.19 Vested and expected to vest at September 30, 20256,271,947 $39.58 At September 30, 2025, there was approximately $32.6 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.46 years.Restricted stock unitsThe following table presents RSU activity for the nine months ended September 30, 2025:Number ofStock UnitsWeighted-AverageGrant Date Fair ValueUnvested shares at December 31, 20241,818,563 $30.31 Granted1,158,801 33.28 Vested(813,892)30.26 Forfeited(108,350)30.80 Unvested shares at September 30, 20252,055,122 $31.98 As of September 30, 2025, there was approximately $47.0 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 1.94 years.Performance-based stock units The following table presents PSU activity for the nine months ended September 30, 2025:Number ofStock UnitsWeighted-AverageGrant Date Fair ValueUnvested shares at December 31, 2024374,583 $29.45 Granted185,450 33.25 Vested(83,027)26.35 Unvested shares